Supplementary Data from 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

Lee, Helen; Shields, Anthony F.; Siegel, Barry A.; Miller, Kathy D.; Krop, Ian; Ma, Cynthia X.; LoRusso, Patricia M.; Munster, Pamela N.; Campbell, Karen; Gaddy, Daniel F.; Leonard, Shannon C.; Geretti, Elena; Blocker, Stephanie J.; Kirpotin, Dmitri B.; Moyo, Victor; Wickham, Thomas J.; Hendriks, Bart S.

doi:10.1158/1078-0432.22469117.v1

- No file added yet -

Supplementary Data from ⁶⁴Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

journal contribution

posted on 2023-03-31, 20:32 authored by Helen Lee, Anthony F. Shields, Barry A. Siegel, Kathy D. Miller, Ian Krop, Cynthia X. Ma, Patricia M. LoRusso, Pamela N. Munster, Karen Campbell, Daniel F. Gaddy, Shannon C. Leonard, Elena Geretti, Stephanie J. Blocker, Dmitri B. Kirpotin, Victor Moyo, Thomas J. Wickham, Bart S. Hendriks

Fig. S1. MM-302 tumor deposition in preclinical xenografts as a function of HER2 expression. Fig. S2. Preclinical assessment of minimum 64Cu-MM-302 tumor delivery for anti-tumor activity. Fig. S3. Maximum intensity projection images of selected patients with average and rapid clearance of 64Cu-MM-302. Fig. S4. Stability of 64Cu-MM-302 in patients. Fig. S5. Hepatic tumor lesion with similar uptake as normal liver tissue. Fig. S6. Estimated parameter values (k1, k-1, VVF) for lesions from 3 patients who underwent 3 scans. Table S1. Model parameters for tracer kinetic modeling of 64Cu-MM-302 liposome transport into and out of tumors. Table S2. Patient Demographic (n=19). Table S3. Radiation Dosimetry of 64Cu-MM-302 (n=11).

History

ARTICLE ABSTRACT

Purpose: Therapeutic nanoparticles are designed to deliver their drug payloads through enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and its variability in human tumors is highly debated and has been proposed as an explanation for variable responses to therapeutic nanoparticles in clinical studies.Experimental Design: We assessed the EPR effect in patients using a 64Cu-labeled nanoparticle, 64Cu-MM-302 (64Cu-labeled HER2-targeted PEGylated liposomal doxorubicin), and imaging by PET/CT. Nineteen patients with HER2-positive metastatic breast cancer underwent 2 to 3 PET/CT scans postadministration of 64Cu-MM-302 as part of a clinical trial of MM-302 plus trastuzumab with and without cyclophosphamide (NCT01304797).Results: Significant background uptake of 64Cu-MM-302 was observed in liver and spleen. Tumor accumulation of 64Cu-MM-302 at 24 to 48 hours varied 35-fold (0.52–18.5 %ID/kg), including deposition in bone and brain lesions, and was independent of systemic plasma exposure. Computational analysis quantified rates of deposition and washout, indicating peak liposome deposition at 24 to 48 hours. Patients were classified on the basis of 64Cu-MM-302 lesion deposition using a cut-off point that is comparable with a response threshold in preclinical studies. In a retrospective exploratory analysis of patient outcomes relating to drug levels in tumor lesions, high 64Cu-MM-302 deposition was associated with more favorable treatment outcomes (HR = 0.42).Conclusions: These findings provide important evidence and quantification of the EPR effect in human metastatic tumors and support imaging nanoparticle deposition in tumors as a potential means to identify patients well suited for treatment with therapeutic nanoparticles. Clin Cancer Res; 23(15); 4190–202. ©2017 AACR.